Korea FDA To Consider Substantial Reduction To IND Timeframe
This article was originally published in PharmAsia News
Executive Summary
As Korea competes with neighboring countries to be a regional clinical trial hub, KFDA weighs the advantages of slashing IND timelines from 30 days down to 14 days.